NEW YORK, June 19, 2014 /PRNewswire/ -- Pomerantz LLP is
investigating claims on behalf of investors of Northwest
Biotherapeutics, Inc. ("Northwest Biotherapeutics" or the
"Company") (NASDAQ: NWBO). Such investors are advised to
contact Robert S. Willoughby at
rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
The investigation concerns whether Northwest Biotherapeutics and
certain of its officers and/or directors have violated Sections
10(b) and 20(a) of the Securities Exchange Act of 1934.
On June 19, 2014, a report
published by the website TheStreet.com states that, "The
prestigious MD Anderson Cancer Center issued a stern rebuke to
Northwest Biotherapeutics (NWBO) for
making promotional, unjustified claims about results from
an ongoing clinical trial of an experimental cancer vaccine
known as DCVax-Direct." MD Anderson Cancer Center is running
the DCVax-Direct clinical trial with funding from Northwest
Biotherapeutics.
On this news, shares of Northwest Biotherapeutics fell
$0.87 per share to $8.04, or more than 10.37%, in intraday trading
on June 19, 2014.
The Pomerantz Firm, with offices in New York, Chicago, San
Diego and Florida, is
acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late
Abraham L. Pomerantz, known as the
dean of the class action bar, the Pomerantz Firm pioneered the
field of securities class actions. Today, more than 70 years later,
the Pomerantz Firm continues in the tradition he established,
fighting for the rights of the victims of securities fraud,
breaches of fiduciary duty, and corporate misconduct. The Firm has
recovered numerous multimillion-dollar damages awards on behalf of
class members. See www.pomerantzlaw.com.
CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
SOURCE Pomerantz LLP